Welcome to our dedicated page for Protagonist Ther SEC filings (Ticker: PTGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Protagonist Therapeutics, Inc. (NASDAQ: PTGX) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures, giving investors structured access to official information the company submits to the U.S. Securities and Exchange Commission. Protagonist identifies itself in these filings as a biopharmaceutical company with principal executive offices in Newark, California, and uses them to report financial results, corporate updates, and other material events.
Among the key documents available are Form 8-K current reports, which Protagonist files to announce specific developments. Recent 8-K filings referenced in company communications include notices of quarterly financial results and corporate updates, as well as the availability of an updated corporate presentation. These filings typically incorporate press releases as exhibits, providing details on clinical milestones for icotrokinra and rusfertide, collaboration arrangements with Johnson & Johnson and Takeda, and financial metrics.
Investors can also use Protagonist’s SEC filings to follow governance and shareholder matters. For example, a Form 8-K describing the 2025 Annual Meeting of Stockholders outlines the election of directors, advisory votes on executive compensation, and ratification of the independent registered public accounting firm. Such disclosures help readers understand how the company’s board composition and oversight framework are presented to shareholders.
On Stock Titan, these filings are paired with AI-powered summaries that explain the main points of lengthy documents in plain language. When Protagonist files quarterly or annual reports, investors can quickly review how the company characterizes its business, pipeline, collaborations, and risks without reading every page. For current reports on clinical or regulatory milestones, AI summaries highlight the aspects most relevant to PTGX, such as references to icotrokinra’s NDA, rusfertide’s Phase 3 data and NDA submission, or updates to the company’s corporate presentation.
In addition, users can monitor real-time updates from EDGAR so that new Protagonist filings appear promptly as they are posted. Where applicable, Stock Titan also surfaces insider transaction reports (Form 4) and proxy materials, giving a consolidated view of trading by officers and directors, compensation-related votes, and other governance topics. Together, these tools help investors interpret Protagonist’s regulatory record and connect formal disclosures to the company’s clinical and collaboration narrative.
Protagonist Therapeutics, Inc. President and CEO Dinesh V. Patel, Ph.D. reported a bona fide gift of 1,460 shares of Common Stock to family and friends. The transaction carried a reported price of $0.00 per share, reflecting that no sale proceeds were received.
Following this gift transfer, Patel directly holds 523,478 shares of Protagonist Therapeutics Common Stock. The filing shows no option exercises or open-market purchases or sales in this transaction, only the non-cash gift disposition.
Protagonist Therapeutics Chief Financial Officer Ali Asif reported an open-market sale of 1,750 shares of common stock at $105.47 per share on April 20, 2026. According to the filing, the sale was made to cover tax withholding obligations triggered by the settlement of restricted stock units.
After this transaction, Asif directly holds 59,003 shares of Protagonist Therapeutics common stock, indicating that the sale represents a small portion of his overall reported holdings.
PTGX Form 144 notice reporting a proposed sale of 1,750 shares of Common Stock tied to restricted stock vesting on 04/20/2026. The filing also lists recent dispositions by a holder: 46,203 shares on 01/27/2026 and 24,765 shares on 03/26/2026.
Protagonist Therapeutics Chief Medical Officer Arturo Molina exercised stock options for 15,000 shares of common stock at an exercise price of $8.04 per share and on the same day sold 15,000 shares at a weighted average price of $104.79 per share. Following these transactions, he directly holds 84,115 shares of common stock. The exercised option was part of a grant from November 7, 2022, with one quarter vested on November 7, 2023 and the remaining three quarters vesting in equal monthly installments through November 7, 2026, conditioned on continuous service.
Protagonist Therapeutics director Harold E. Selick reported an option exercise and share sale. He exercised stock options for 24,000 shares of common stock at $12.88 per share, converting fully vested options into common shares.
On the same date, he then sold 24,000 common shares at $105.00 per share in an open-market transaction. Following these transactions, Selick directly holds 60,845 shares of Protagonist Therapeutics common stock.
Protagonist Therapeutics Chief Financial Officer Asif Ali exercised employee stock options and sold shares on the same day. He exercised options to acquire 19,500 shares of common stock at $19.19 per share and 5,265 shares at $12.17 per share. He then sold 24,765 shares of common stock in open-market transactions at a weighted average price of $104.24 per share, with individual trades ranging from $104.00 to $104.465. After these transactions, he directly owned 60,753 common shares, which include 433 shares acquired under the company’s 2016 Employee Stock Purchase Plan on March 9, 2026.
The Vanguard Group amended a Schedule 13G/A to report 0% beneficial ownership of Protagonist Therapeutics Inc common stock. The filing states that, following an internal realignment on January 12, 2026, certain Vanguard subsidiaries now report holdings separately in reliance on SEC Release No. 34-39538, and Vanguard no longer is deemed to beneficially own those securities. The amendment is signed by Ashley Grim, Head of Global Fund Administration, dated 03/27/2026.
PTGX Form 144 shows recent proposed and completed sales of Common Stock. The excerpt lists a planned stock option exercise to sell 24,765 shares for cash on 03/26/2026. It also records two completed sales by Asif Ali: 46,203 shares on 01/27/2026 for $3,841,128.28 and 8,588 shares on 01/20/2026 for $708,327.08. Shares outstanding are listed as 63,808,716 as of 03/26/2026.
PTGX submitted a Form 144 reporting the sale of 15,000 shares via a stock option exercise to be settled for cash on 03/26/2026. The filing lists prior open-market dispositions by Arturo Molina, including 5,000 shares on 01/27/2026 and 13,151 shares on 01/23/2026.